DE102007001370A1
(de)
*
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
EP2324131A4
(de)
*
|
2008-09-17 |
2013-02-27 |
Ge Healthcare Bio Sciences |
Verfahren zur isolierung kleiner rna
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
EP2955230A1
(de)
|
2010-07-30 |
2015-12-16 |
CureVac AG |
Komplexierung von nukleinsäuren mit disulfid-vernetzten kationischen komponenten zur transfektion und immunstimulation
|
EP3578205A1
(de)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9428535B2
(en)
|
2011-10-03 |
2016-08-30 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
LT2791160T
(lt)
|
2011-12-16 |
2022-06-10 |
Modernatx, Inc. |
Modifikuotos mrnr sudėtys
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
KR20140139101A
(ko)
|
2012-03-27 |
2014-12-04 |
큐어백 게엠바하 |
5''top utr을 포함하는 인공 핵산 분자
|
DK2831241T3
(da)
|
2012-03-27 |
2017-11-06 |
Curevac Ag |
Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
|
CA2866955A1
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9192651B2
(en)
|
2012-04-02 |
2015-11-24 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
SG10201710473VA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
CA2903487A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Quantitative assessment for cap efficiency of messenger rna
|
PL2970948T3
(pl)
|
2013-03-15 |
2019-06-28 |
Glaxosmithkline Biologicals Sa |
Sposoby oczyszczania rna
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
WO2014144711A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
EP2971161B1
(de)
|
2013-03-15 |
2018-12-26 |
ModernaTX, Inc. |
Nukleinsäurereinigung
|
EP2971165A4
(de)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
Entfernung von dna-fragmenten in mrna-herstellungsverfahren
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
EP2996697B1
(de)
|
2013-05-15 |
2019-06-26 |
Robert Kruse |
Intrazelluläre translation von zirkulärer rna
|
JP7019233B2
(ja)
|
2013-07-11 |
2022-02-15 |
モデルナティエックス インコーポレイテッド |
CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法
|
KR102354389B1
(ko)
|
2013-08-21 |
2022-01-20 |
큐어백 아게 |
Rna―암호화된 단백질의 발현을 증가시키는 방법
|
EP3450561A1
(de)
|
2013-08-21 |
2019-03-06 |
CureVac AG |
Verfahren zur erhöhung der expression von rna-codierten proteinen
|
EP3035960B1
(de)
|
2013-08-21 |
2019-07-03 |
CureVac AG |
Impfstoff gegen das respiratorische synzytialvirus
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
EP4043032A1
(de)
|
2013-08-21 |
2022-08-17 |
CureVac AG |
Tollwutimpfstoff
|
ES2747762T3
(es)
|
2013-08-21 |
2020-03-11 |
Curevac Ag |
Vacuna contra el virus respiratorio sincitial (RSV)
|
WO2015024669A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Combination vaccine
|
EP3052106A4
(de)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynukleotide zur codierung immunmodulierender polypeptide
|
EP3052511A4
(de)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynukleotidmoleküle und verwendungen davon
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
EP3542802A1
(de)
|
2013-11-01 |
2019-09-25 |
CureVac AG |
Modifizierte rna mit verminderten immunstimulierenden eigenschaften
|
SG10201903381TA
(en)
|
2013-12-30 |
2019-05-30 |
Curevac Ag |
Artificial nucleic acid molecules
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
SG10201805660WA
(en)
|
2013-12-30 |
2018-08-30 |
Curevac Ag |
Methods for rna analysis
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
EP3540060A1
(de)
|
2013-12-30 |
2019-09-18 |
CureVac AG |
Verfahren zur rna-analyse
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
US10369216B2
(en)
|
2014-04-01 |
2019-08-06 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
CN106659803A
(zh)
|
2014-04-23 |
2017-05-10 |
摩登纳特斯有限公司 |
核酸疫苗
|
BR112016026980B1
(pt)
|
2014-06-10 |
2022-05-03 |
Curevac Real Estate Gmbh |
Método para sintetizar uma molécula de rna de uma dada sequência
|
EP3157573A4
(de)
|
2014-06-19 |
2018-02-21 |
Moderna Therapeutics, Inc. |
Alternative nukleinsäuremoleküle und verwendungen davon
|
JP2017522028A
(ja)
|
2014-07-16 |
2017-08-10 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
環状ポリヌクレオチド
|
EP4241784A3
(de)
|
2014-12-12 |
2023-11-15 |
CureVac SE |
Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression
|
US10653768B2
(en)
|
2015-04-13 |
2020-05-19 |
Curevac Real Estate Gmbh |
Method for producing RNA compositions
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
EP3289101B1
(de)
|
2015-04-30 |
2021-06-23 |
CureVac AG |
Immobilisierte poly(n)polymerase
|
DK3294885T3
(da)
|
2015-05-08 |
2020-08-10 |
Curevac Real Estate Gmbh |
Fremgangsmåde til at fremstille rna
|
CA2975816A1
(en)
|
2015-05-15 |
2016-11-24 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mrna construct
|
EP3297682B1
(de)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Trockenpulverzusammensetzung mit langkettiger rna
|
SG11201708540VA
(en)
|
2015-05-20 |
2017-12-28 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
PT4108769T
(pt)
|
2015-05-29 |
2023-10-10 |
Curevac Mfg Gmbh |
Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
EP3317424B1
(de)
*
|
2015-07-01 |
2023-09-06 |
CureVac Manufacturing GmbH |
Verfahren zur analyse eines rna-moleküls
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
WO2017064146A1
(en)
|
2015-10-12 |
2017-04-20 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
ES2914225T3
(es)
|
2015-10-16 |
2022-06-08 |
Modernatx Inc |
Análogos de cap de ARNm con enlace de fosfato modificado
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
mRNAキャップ類似体およびmRNAキャッピングの方法
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
EP3373965A1
(de)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus-impfstoffe
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
CN108778308A
(zh)
|
2015-12-22 |
2018-11-09 |
库瑞瓦格股份公司 |
生产rna分子组合物的方法
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
WO2017137095A1
(en)
|
2016-02-12 |
2017-08-17 |
Curevac Ag |
Method for analyzing rna
|
WO2017140345A1
(en)
|
2016-02-15 |
2017-08-24 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
SG10201913630YA
(en)
|
2016-02-17 |
2020-03-30 |
Curevac Ag |
Zika virus vaccine
|
WO2017149139A1
(en)
|
2016-03-03 |
2017-09-08 |
Curevac Ag |
Rna analysis by total hydrolysis
|
LT3445850T
(lt)
|
2016-04-22 |
2021-11-25 |
BioNTech SE |
Viengrandės rnr gavimo būdas
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
US11141474B2
(en)
|
2016-05-04 |
2021-10-12 |
Curevac Ag |
Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
|
EP3452101A2
(de)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna-codierung eines therapeutischen proteins
|
WO2017212006A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
EP3468609A1
(de)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Kationische träger zur nukleinsäurefreisetzung
|
MX2018013919A
(es)
|
2016-06-09 |
2019-04-15 |
Curevac Ag |
Portadores hibridos para cargas de acido nucleico.
|
CA3027201A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
CA3025812A1
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
WO2018041921A1
(en)
|
2016-08-31 |
2018-03-08 |
Curevac Ag |
Mixing device for the production of a liquid nucleic acid composition
|
WO2018053209A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
KR20190093816A
(ko)
|
2016-10-26 |
2019-08-26 |
큐어백 아게 |
지질 나노입자 mRNA 백신
|
EP3538067A1
(de)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilisierte formulierungen von lipidnanopartikeln
|
WO2018096179A1
(en)
*
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
EP4035659A1
(de)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosome zur ausgabe von therapeutischen wirkstoffen
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
EP3551230A1
(de)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna zur behandlung oder prophylaxe einer lebererkrankung
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
EP3558354A1
(de)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Impfstoff gegen das lassa-virus
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
WO2018141371A1
(en)
|
2017-01-31 |
2018-08-09 |
Curevac Ag |
Purification and/or formulation of rna
|
HUE060693T2
(hu)
|
2017-03-15 |
2023-04-28 |
Modernatx Inc |
Vegyület és készítmények terápiás szerek intracelluláris bejuttatására
|
US11969506B2
(en)
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
|
AU2018240515A1
(en)
|
2017-03-24 |
2019-08-01 |
CureVac SE |
Nucleic acids encoding CRISPR-associated proteins and uses thereof
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
WO2018211038A1
(en)
|
2017-05-17 |
2018-11-22 |
Curevac Ag |
Method for determining at least one quality parameter of an rna sample
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
US10034951B1
(en)
|
2017-06-21 |
2018-07-31 |
New England Biolabs, Inc. |
Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
MA49922A
(fr)
*
|
2017-08-18 |
2021-06-02 |
Modernatx Inc |
Procédés pour analyse par clhp
|
EP3668977A4
(de)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
Analytische hplc-verfahren
|
US20200362382A1
(en)
|
2017-08-18 |
2020-11-19 |
Modernatx, Inc. |
Methods of preparing modified rna
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
SG11202003247RA
(en)
|
2017-11-08 |
2020-05-28 |
Curevac Ag |
Rna sequence adaptation
|
EP3723796A1
(de)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus-impfstoff
|
US11525158B2
(en)
|
2017-12-21 |
2022-12-13 |
CureVac SE |
Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
|
EP3773702A2
(de)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Neue gelbfieber-nukleinsäuremoleküle zur impfung
|
EP3781591A1
(de)
|
2018-04-17 |
2021-02-24 |
CureVac AG |
Neuartige rsv-rna-moleküle und zusammensetzungen zur impfung
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
BR112020025601A8
(pt)
|
2018-06-28 |
2022-07-05 |
Tesla Automation GmbH |
Biorreator para a transcrição in vitro de rna
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
JP2022501367A
(ja)
|
2018-09-20 |
2022-01-06 |
モデルナティエックス インコーポレイテッドModernaTX, Inc. |
脂質ナノ粒子の調製及びその投与方法
|
CA3114892A1
(en)
|
2018-10-04 |
2020-04-09 |
New England Biolabs, Inc. |
Methods and compositions for increasing capping efficiency of transcribed rna
|
US11072808B2
(en)
|
2018-10-04 |
2021-07-27 |
New England Biolabs, Inc. |
Methods and compositions for increasing capping efficiency of transcribed RNA
|
EP3897702A2
(de)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna für malaria-impfstoffe
|
MX2021009245A
(es)
|
2019-01-31 |
2021-11-12 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
MX2021009236A
(es)
|
2019-01-31 |
2021-11-12 |
Modernatx Inc |
Agitadores vorticiales y metodos, sistemas y aparatos asociados de estos.
|
EP3920950A1
(de)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
In den suprachoroidalen raum verabreichte codierende rna zur behandlung von augenerkrankungen
|
EP3986452A1
(de)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus-mrna-impfstoff
|
BR112022001947A2
(pt)
|
2019-08-14 |
2022-09-20 |
Curevac Ag |
Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
|
EP4076647A1
(de)
|
2019-12-20 |
2022-10-26 |
CureVac AG |
Lipidnanopartikel zur verabreichung von nukleinsäuren
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
DE112021000012B4
(de)
|
2020-02-04 |
2023-08-31 |
CureVac SE |
Coronavirus-Vakzine
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
EP4127704A1
(de)
*
|
2020-03-25 |
2023-02-08 |
Waters Technologies Corporation |
Vorrichtungen und verfahren für den empfindlichen nachweis und die quantifizierung von biomolekülen
|
AU2021254312B2
(en)
|
2020-04-09 |
2024-01-11 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid nanoparticle composition
|
TW202204622A
(zh)
|
2020-04-09 |
2022-02-01 |
大陸商蘇州艾博生物科技有限公司 |
針對冠狀病毒之核酸疫苗
|
EP3993828A1
(de)
|
2020-05-29 |
2022-05-11 |
CureVac AG |
Kombinationsimpfstoffe auf nukleinsäurebasis
|
WO2021254593A1
(en)
|
2020-06-15 |
2021-12-23 |
Curevac Ag |
Analysis of nucleic acid mixtures
|
JP2023532707A
(ja)
|
2020-06-30 |
2023-07-31 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
US20230272052A1
(en)
|
2020-07-31 |
2023-08-31 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
AU2021328980A1
(en)
|
2020-08-20 |
2023-03-09 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
EP4208286A1
(de)
|
2020-09-01 |
2023-07-12 |
CureVac RNA Printer GmbH |
Herstellungsvorrichtung für ein pharmazeutisches produkt
|
WO2022112498A1
(en)
|
2020-11-27 |
2022-06-02 |
CureVac RNA Printer GmbH |
A device for preparing a dna product by means of capillary polymerase chain reaction
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
AU2021405281A1
(en)
|
2020-12-22 |
2023-07-06 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
CN116615472A
(zh)
|
2021-01-14 |
2023-08-18 |
苏州艾博生物科技有限公司 |
聚合物缀合的脂质化合物和脂质纳米颗粒组合物
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
WO2022164428A1
(en)
|
2021-01-27 |
2022-08-04 |
New England Biolabs, Inc. |
Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
US11028379B1
(en)
|
2021-01-27 |
2021-06-08 |
New England Biolabs, Inc. |
FCE mRNA capping enzyme compositions, methods and kits
|
CN117377491A
(zh)
|
2021-03-26 |
2024-01-09 |
葛兰素史克生物有限公司 |
免疫原性组合物
|
EP4312988A2
(de)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Spritzen mit pharmazeutischen zusammensetzungen mit rna
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
WO2022240960A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Crispr Therapeutics Ag |
Mrna large scale synthesis and purification
|
WO2022247755A1
(en)
|
2021-05-24 |
2022-12-01 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
WO2022256597A1
(en)
|
2021-06-04 |
2022-12-08 |
Translate Bio, Inc. |
Assay for quantitative assessment of mrna capping efficiency
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
WO2023007019A1
(en)
|
2021-07-30 |
2023-02-02 |
CureVac SE |
Cap analogs having an acyclic linker to the guanine derivative nucleobase
|
WO2023014649A1
(en)
|
2021-08-02 |
2023-02-09 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
AU2022336209A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
WO2023031392A2
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
KR102646914B1
(ko)
*
|
2021-10-01 |
2024-03-12 |
서울대학교산학협력단 |
아실글리세롤 이성질체 및 자유지방산 직접 동시분석법 및 이를 통한 라이페이스 입체선택성 분석법
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
WO2023056917A1
(en)
|
2021-10-08 |
2023-04-13 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
WO2023196950A1
(en)
|
2022-04-07 |
2023-10-12 |
New England Biolabs, Inc. |
Methods of higher fidelity rna synthesis
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024030369A1
(en)
|
2022-08-01 |
2024-02-08 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
WO2024037578A1
(en)
|
2022-08-18 |
2024-02-22 |
Suzhou Abogen Biosciences Co., Ltd. |
Composition of lipid nanoparticles
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
CN115774075B
(zh)
*
|
2023-02-15 |
2023-06-06 |
江苏耀海生物制药有限公司 |
一种基于RP-HPLC分析体外转录产物成分circRNA的方法
|